Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Development of long-acting nitrate delivery systems.

Literature DB >> 2113000

Development of long-acting nitrate delivery systems.

Abstract

In this paper pharmaceutical and biopharmaceutical aspects on the development of long-acting nitrate delivery systems are reviewed. Basic considerations and requirements are also discussed. Recent product development activities are presented, with an emphasis on nitroglycerin in transdermal form and oral isosorbide-5-mononitrate controlled-release formulations.

Entities: Chemical

Mesh：

Substances：

Year: 1990 PMID： 2113000 DOI： 10.1007/bf01417560

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

23 in total

1. Prevention of tolerance to nitroglycerin patches by overnight removal.

Authors: J C Cowan; J P Bourke; D S Reid; D G Julian
Journal: Am J Cardiol Date: 1987-08-01 Impact factor: 2.778

2. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].

Authors: T Skutta; B Böttcher; L Brandt
Journal: Arzneimittelforschung Date: 1989-04

3. Performance of a slow-release formulation of isosorbide-5-mononitrate (ISMO retard).

Authors: G Neugebauer; W Akpan; B Stemmle; H Jaeger; H Mosberg; D Lutz
Journal: Int J Clin Pharmacol Ther Toxicol Date: 1989-01

4. Investigation of the gastrointestinal transit and in vivo drug release of isosorbide-5-nitrate pellets.

Authors: W Fischer; A Boertz; S S Davis; R Khosla; W Cawello; K Sandrock; G Cordes
Journal: Pharm Res Date: 1987-12 Impact factor: 4.200

5. Studies on a sustained release principle based on an inert plastic matrix.

Authors: J Sjögren
Journal: Acta Pharm Suec Date: 1971-06

6. The effect of isosorbide-5-mononitrate (5-ISMN) Durules on exercise tolerance in patients with exertional angina pectoris. A placebo controlled study.

Authors: G Nyberg; P Carlens; E Lindström; T Lundman; R Nordlander; N Rehnqvist; G Ulvenstam; A Aberg; H Aström
Journal: Eur Heart J Date: 1986-10 Impact factor: 29.983

7. Improved skin adherence and patient acceptance in a new transdermal nitroglycerin delivery system.

Authors: A J Hougham; R W Hawkinson; J K Crowley; R R Wilson; J E Glode; R W Hilty; S O Hughes; C G Koeppl; T R Kovaric; N P Wyskoarko
Journal: Clin Ther Date: 1989 Impact factor: 3.393

8. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy.

Authors: U Thadani; H L Fung; A C Darke; J O Parker
Journal: Am J Cardiol Date: 1982-02-01 Impact factor: 2.778

9. Ambulatory heart rate and ST-segment depression during painful and silent myocardial ischemia in chronic stable angina pectoris.

Authors: G P Carboni; A Lahiri; P M Cashman; E B Raftery
Journal: Am J Cardiol Date: 1987-05-01 Impact factor: 2.778

3. The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.

Authors: W McClennen; B Hornestam; U E Jonsson; P Held
Journal: Br J Clin Pharmacol Date: 1995-06 Impact factor: 4.335

3 in total